

Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

Nov 13 2018, 9:05 AM EST

SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

Oct 23 2018, 9:00 AM EDT

SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Oct 15 2018, 9:26 AM EDT

Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	39.49m
Last Price	\$0.84
52-Week	\$0.885 - \$2.45

11/13/2018 04:00 PM EST

Investor Relations

Argot Partners
Natalie Wildenradt
T: 212-600-1902
natalie@argotpartners.com

Leadership

Marco Taglietti, M.D.

President and Chief Executive Officer

David Angulo, M.D.

Chief Medical Officer

Eric Francois

Chief Financial Officer

Scott Sukenick

General Counsel

SCYNEXIS, Inc.

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.